CO5680404A2 - Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk - Google Patents
Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtkInfo
- Publication number
- CO5680404A2 CO5680404A2 CO06016491A CO06016491A CO5680404A2 CO 5680404 A2 CO5680404 A2 CO 5680404A2 CO 06016491 A CO06016491 A CO 06016491A CO 06016491 A CO06016491 A CO 06016491A CO 5680404 A2 CO5680404 A2 CO 5680404A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- hydrogen
- substituted
- alkylene
- Prior art date
Links
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical class [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 2
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Abstract
1.- Un compuesto de la fórmula: en la cual:R1 se selecciona a partir de hidrógeno, halógeno, alquilo de C1-6, alquilo de C1-6 sustituido con halógeno, alcoxi de C1-6, alcoxi de C1-6 sustituido con halógeno, -OXOR5, -OXR6, -OXNRsR6, -OXONR5R6, -XR6,- XNR5R6 y -XNR7XNR7R7; en los cuales X se selecciona a partir de un enlace, alquileno de C1-6, alquenileno de C2-6 y alquinileno de C2-6; en los cuales R7 se selecciona de manera independiente a partir de hidrógeno o alquilo de C1-6;R5 se selecciona a partir de hidrógeno, alquilo de C1-6 y -XOR7; en el cual X se selecciona a partir de un enlace, alquileno de C1-6, alquenileno de C2-6 y alquinileno de C2-6; y R7 se selecciona de manera independiente a partir de hidrógeno o alquilo de C1-6;R6 se selecciona a partir de hidrógeno, alquilo de C1-6, cicloalquil(C3-12)-alquilo de C0-4, heterocicloalquil(C3-8)-alquilo de C0-4, aril(C6-10)-alquilo de C0-4 y heteroaril(C5-10)-alquilo de C0-4; o R5 y R6 junto con el átomo de nitrógeno al cual están unidos ambos R5 y R6 forman heterocicloaIquilo de C3-8 o heteroarilo d e C5-8; en eI cuaI un metileno de cuaIquier heterocicloalquilo formado por R5 y R6 puede estar reemplazado opcionalmente con -C(O)- o S(O)2-;en la cual cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R6 o la combinación de R5 y R6 puede estar sustituido opcionalmente con 1 a 3 radicales que se seleccionan de manera independiente a partir de -XNR7R7, -XOR7, -XNR7R7, -XC(O)NR7R7, -XNR7C(O)R7, -XOR7, -XC(O)OR7, -XC(O)R7, alquilo de C1-6, heterocicloalquilo de C3-8, heteroarilo de C5-10, cicloalquilo de C3-12 y aril(C6-10)-alquilo de C0-4; en los cuales cualquier alquilo o alquileno de R1 puede tener opcionalmente un metileno reemplazado por un radical divalente que se selecciona a partir de -NR7C(O)-, -C(O)NR7-, -NR7-, -C(O)-, -O-, -S-, -S(O)- y -S(O)2-; y en el cual cualquier alquilo o alquileno de R6 puede estar sustituido opcionalmente con 1 a 3 radicales que se seleccionan de manera independiente a partir de heteroarilo de C5-8, -NR7R7, -C(O)NR7R7, -NR7C(O)R7, ...
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49540603P | 2003-08-15 | 2003-08-15 | |
US52435703P | 2003-11-21 | 2003-11-21 | |
US56536704P | 2004-04-26 | 2004-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5680404A2 true CO5680404A2 (es) | 2006-09-29 |
Family
ID=34198974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO06016491A CO5680404A2 (es) | 2003-08-15 | 2006-02-20 | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk |
Country Status (16)
Country | Link |
---|---|
US (2) | US20050124637A1 (es) |
EP (1) | EP1656378A4 (es) |
JP (1) | JP2007502776A (es) |
AU (2) | AU2004264419B2 (es) |
BR (1) | BRPI0413563A (es) |
CA (1) | CA2535620A1 (es) |
CO (1) | CO5680404A2 (es) |
EC (1) | ECSP066365A (es) |
IL (1) | IL173392A0 (es) |
IS (1) | IS8345A (es) |
MA (1) | MA27997A1 (es) |
MX (1) | MXPA06001758A (es) |
NO (1) | NO20061074L (es) |
SG (1) | SG145748A1 (es) |
TN (1) | TNSN06053A1 (es) |
WO (1) | WO2005016528A2 (es) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002342051B2 (en) * | 2001-10-12 | 2009-06-11 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
US7273864B2 (en) * | 2002-10-15 | 2007-09-25 | The Scripps Research Institute | Compositions and methods for inducing osteogenesis |
WO2005028479A2 (en) * | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
US7256196B1 (en) | 2003-12-09 | 2007-08-14 | The Procter & Gamble Company | Purine cytokine inhibitors |
US20070197559A1 (en) * | 2004-03-02 | 2007-08-23 | Rajagopal Bakthavatchalam | Aryl substituted purine analogues |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
DE102005017259A1 (de) * | 2005-04-14 | 2006-10-19 | Merck Patent Gmbh | Purinderivate |
EP1891066B1 (en) * | 2005-05-13 | 2010-12-22 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
JP5108752B2 (ja) * | 2005-05-16 | 2012-12-26 | プロメティック・バイオサイエンスィズ・インコーポレーテッド | 自己免疫疾患を治療するための化合物とそれら化合物の使用 |
CN100526315C (zh) * | 2005-06-16 | 2009-08-12 | 浙江医药股份有限公司新昌制药厂 | N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途 |
EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
ES2562428T3 (es) | 2005-12-15 | 2016-03-04 | Rigel Pharmaceuticals, Inc. | Inhibidores de cinasa y sus usos |
CA2647391C (en) | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
AU2007333394C1 (en) * | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
EP3012249A1 (en) | 2006-12-08 | 2016-04-27 | Novartis AG | Compounds and composition as protein kinase inhibitors |
EA200900983A1 (ru) * | 2007-01-26 | 2010-02-26 | Айрм Ллк | Соединения и композиции в качестве ингибиторов киназы |
CN101679422A (zh) * | 2007-03-28 | 2010-03-24 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
US20100105705A1 (en) * | 2007-03-28 | 2010-04-29 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
EP2142546B1 (en) * | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
CN101289449A (zh) * | 2007-04-20 | 2008-10-22 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用 |
WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
CZ302225B6 (cs) * | 2007-07-04 | 2010-12-29 | Univerzita Palackého v Olomouci | Substituované 6-anilinopurinové deriváty jako inhibitory cytokinin oxidasy a prípravky obsahující tyto slouceniny |
FR2920776B1 (fr) * | 2007-09-12 | 2012-09-28 | Centre Nat Rech Scient | Utilisation de derives de purine pour la fabrication d'un medicament |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
AU2013205510A1 (en) * | 2008-05-21 | 2013-05-16 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
CA2723961C (en) * | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
WO2010006086A2 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
JP2011530511A (ja) * | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
US8268838B2 (en) * | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
WO2010034706A1 (en) * | 2008-09-26 | 2010-04-01 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
WO2010059418A1 (en) * | 2008-11-19 | 2010-05-27 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
AR076601A1 (es) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | Pirimidinas como agentes terapeuticos |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
CN102947302A (zh) | 2010-02-18 | 2013-02-27 | 西班牙国家癌症研究中心 | ***并[4,5-b]吡啶衍生物 |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
AU2012223279A1 (en) * | 2011-03-01 | 2013-09-26 | Sloan-Kettering Institute For Cancer Research | Parathyroid hormone analogs, compositions and uses thereof |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
WO2012172043A1 (en) | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
WO2013130461A1 (en) | 2012-02-29 | 2013-09-06 | The Scripps Research Institute | Wee1 degradation inhibitors |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
BR112015006828A8 (pt) | 2012-09-26 | 2019-09-17 | Univ California | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104418858B (zh) * | 2013-08-30 | 2018-12-11 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用 |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
CN117800973A (zh) | 2015-02-27 | 2024-04-02 | 因赛特控股公司 | Pi3k抑制剂的盐及其制备方法 |
CN104788387A (zh) * | 2015-04-17 | 2015-07-22 | 浙江海森药业有限公司 | 高纯度瑞舒伐他汀钙的制备方法 |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
EP3528816A4 (en) * | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
CZ308029B6 (cs) | 2017-03-20 | 2019-11-06 | Univerzita PalackĂ©ho v Olomouci | 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky |
US11331313B2 (en) | 2017-05-22 | 2022-05-17 | Whitehead Institute For Biomedical Research | KCC2 expression enhancing compounds and uses thereof |
US20220242866A1 (en) * | 2019-06-24 | 2022-08-04 | Merck Sharp & Dohme Corp. | Process for the preparation of 2-fluoroadenine |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3041340A (en) * | 1962-06-26 | Method of preparing substituted | ||
US3133065A (en) * | 1962-07-30 | 1964-05-12 | Abbott Lab | Purine derivatives |
US4405781A (en) * | 1981-03-02 | 1983-09-20 | Polaroid Corporation | Method for preparing salts of 6-chloropurine |
US5565566A (en) * | 1987-04-24 | 1996-10-15 | Discovery Therapeutics, Inc. | N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists |
US5017578A (en) * | 1989-06-09 | 1991-05-21 | Hoechst-Roussel Pharmaceuticals Inc. | N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents |
BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
US5744424A (en) * | 1993-12-03 | 1998-04-28 | Caudill Seed Company, Inc. | Plant growth promoter composition comprising N-6-benzyladenine, an alcohol, and a metal hydroxide |
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
ES2159760T3 (es) * | 1995-11-14 | 2001-10-16 | Pharmacia & Upjohn Spa | Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina. |
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
GB9903762D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
AU7323000A (en) * | 1999-08-26 | 2001-04-10 | Plant Research International B.V. | Conditional inhibition of vegetative propagation |
EA200200424A1 (ru) * | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
JP4443215B2 (ja) * | 2001-02-08 | 2010-03-31 | メモリ ファーマセチカル コーポレーション | ホスホジエステラーゼ4阻害剤としてのトリフルオロメチルプリン |
CZ294535B6 (cs) * | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
JP2005506350A (ja) * | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
US7273864B2 (en) * | 2002-10-15 | 2007-09-25 | The Scripps Research Institute | Compositions and methods for inducing osteogenesis |
EP1444982A1 (de) * | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
EA200900983A1 (ru) * | 2007-01-26 | 2010-02-26 | Айрм Ллк | Соединения и композиции в качестве ингибиторов киназы |
-
2004
- 2004-08-13 MX MXPA06001758A patent/MXPA06001758A/es not_active Application Discontinuation
- 2004-08-13 CA CA002535620A patent/CA2535620A1/en not_active Abandoned
- 2004-08-13 BR BRPI0413563-6A patent/BRPI0413563A/pt not_active IP Right Cessation
- 2004-08-13 US US10/917,578 patent/US20050124637A1/en not_active Abandoned
- 2004-08-13 EP EP04781114A patent/EP1656378A4/en not_active Withdrawn
- 2004-08-13 JP JP2006523409A patent/JP2007502776A/ja active Pending
- 2004-08-13 SG SG200806062-6A patent/SG145748A1/en unknown
- 2004-08-13 WO PCT/US2004/026373 patent/WO2005016528A2/en active Application Filing
- 2004-08-13 AU AU2004264419A patent/AU2004264419B2/en not_active Ceased
-
2006
- 2006-01-26 IL IL173392A patent/IL173392A0/en unknown
- 2006-02-14 EC EC2006006365A patent/ECSP066365A/es unknown
- 2006-02-14 TN TNP2006000053A patent/TNSN06053A1/en unknown
- 2006-02-17 MA MA28818A patent/MA27997A1/fr unknown
- 2006-02-20 CO CO06016491A patent/CO5680404A2/es not_active Application Discontinuation
- 2006-03-06 NO NO20061074A patent/NO20061074L/no not_active Application Discontinuation
- 2006-03-09 IS IS8345A patent/IS8345A/is unknown
-
2009
- 2009-04-15 AU AU2009201480A patent/AU2009201480A1/en not_active Abandoned
-
2010
- 2010-12-22 US US12/976,187 patent/US20110092491A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0413563A (pt) | 2006-10-17 |
SG145748A1 (en) | 2008-09-29 |
WO2005016528A3 (en) | 2005-05-12 |
AU2009201480A1 (en) | 2009-05-14 |
MA27997A1 (fr) | 2006-07-03 |
TNSN06053A1 (en) | 2007-10-03 |
IL173392A0 (en) | 2006-06-11 |
NO20061074L (no) | 2006-03-06 |
IS8345A (is) | 2006-03-09 |
US20110092491A1 (en) | 2011-04-21 |
EP1656378A4 (en) | 2011-05-11 |
MXPA06001758A (es) | 2006-08-11 |
AU2004264419A1 (en) | 2005-02-24 |
ECSP066365A (es) | 2006-08-30 |
EP1656378A2 (en) | 2006-05-17 |
WO2005016528A2 (en) | 2005-02-24 |
AU2004264419B2 (en) | 2009-01-15 |
CA2535620A1 (en) | 2005-02-24 |
JP2007502776A (ja) | 2007-02-15 |
US20050124637A1 (en) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5680404A2 (es) | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk | |
CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
AR103812A2 (es) | Derivados de piperidina antagonistas de nk1 | |
AR049543A1 (es) | Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica | |
ES2603931T3 (es) | Compuestos de triazolo | |
EA200800175A1 (ru) | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB | |
ECSP12012212A (es) | Derivados de ariletinilo | |
EP1719765A4 (en) | NEW SULFONAMIDE DERIVATIVE | |
AR059620A1 (es) | Moduladores pirrolo - piridinicos de quinasas | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
EA200300813A1 (ru) | Огнезащитные реагенты | |
NO20034595L (no) | Kinolin- og kinazolinderivater med azolylgruppe | |
CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
AR076235A1 (es) | Compuestos organicos y sus usos | |
AR049089A1 (es) | Derivados de adamantil pirrolidin -2- ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa | |
DK1414797T3 (da) | Hepatitis C-viruspolymeraseinhibitorer med en heterobicyklisk struktur | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
NO20082976L (no) | Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer | |
CO6321168A2 (es) | Nuevos derivados de 2-amidotiadiazol | |
CO5580762A2 (es) | Analogos de lipoxina a4 | |
ATE526321T1 (de) | Neue epoxidverbindung, alkalisch entwickelbare harzzusammensetzung und alkalisch entwickelbare lichtempfindliche harzzusammensetzung | |
AR036501A1 (es) | Metodo para la sintesis de hexahidro-furo[2,3-b]furan-3-ol, e intermediarios | |
AR042827A1 (es) | Compuestos de furano condensados | |
CY1115635T1 (el) | Παραγωγα 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |